Designing microbiome therapies at scale starts with manufacturing As the field moves from fecal transplants toward defined bacterial consortia, the technical gaps in design, analytics, and co-cultivation are coming into sharper focus. Written byAndrea Corona

https://www.drugdiscoverynews.com/designing-microbiome-therapies-at-scale-starts-with-manufacturing-17183 Microbiome-based therapeutics have accumulated a compelling body of clinical evidence over the past decade. What they have lacked is the manufacturing and design infrastructure to turn that rationale into reproducible, scalable drugs. Munich-based mbiomics is attempting to build that infrastructure.